No Data
No Data
Sunflower Pharmaceutical Group (002737.SZ): The Ursodeoxycholic Acid Capsules have been accepted for market approval.
On October 14, Gelonghui reported that Sunflower Pharmaceutical Group (002737.SZ) announced that its holding subsidiary, Sunflower Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd. recently received the "Acceptance Notice" issued by the National Medical Products Administration for the application for registration and listing of Ursodeoxycholic Acid Capsules. The intended indications (or main functions) of the above-mentioned pharmaceutical are: (1) Gallbladder cholesterol stones must be stones that can be penetrated by X-rays, and the gallbladder contraction function must be normal; (2) Biliary stasis liver disease (such as primary biliary cirrhosis); (3) Bile reflux gastritis.
Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Three-year Earnings Growth Trails the Respectable Shareholder Returns
Sunflower Pharmaceutical: Semi-Annual Report 2024
Sunflower Pharmaceutical: 2024 Semi-Annual Report Summary
Sunflower Pharmaceutical Group (002737.SZ) released its half-year performance. The net income was 0.486 billion yuan, a decrease of 23.79% compared to the same period last year.
Sunflower Pharmaceutical Group (002737.SZ) released its 2024 interim report, with revenue of 2.527 billion yuan, a year-on-year...
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Shares Lagging The Market But So Is The Business
No Data
No Data